bca101
mAbexperimentalMulti-specific
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
1
Phase 4
0
Earliest trial started Jun 1, 2020 (NCT04429542)
Timeline
Indications
Studied for
- Carcinoma, Ovarian Epithelial · Phase 1
- Carcinoma, Squamous Cell · Phase 1
- Colorectal Neoplasms · Phase 1
- Epidermal Growth Factor · Phase 1
- Head and Neck Neoplasms · Phase 1
- Lung Neoplasms · Phase 1
- Pancreatic Neoplasms · Phase 1
- Rectal Neoplasms · Phase 1
- Squamous Cell Carcinoma of Head and Neck · Phase 2/Phase 3
Mechanism of action
EGFR inhibitor
- Transforming growth factor beta-1INHIBITOR
TGFB1 inhibitor
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095314 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06788990 | Phase 2/Phase 3 (Phase 3) | Jan 28, 2025 | Biocon Limited |
| NCT04429542 | Phase 1 | Jun 1, 2020 | Biocon Limited |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biocon Limited | For profit | 2 | 2 | 2 | 2020 |
1 organizations
Page 1 / 1